Search

Displaying results 6321 - 6330 of 10000 in total
  1. Drug

    Alferminogene tadenovec

    go.drugbank.com/drugs/DB05306
    Investigational

    Alferminogene tadenovec, Cardium’s lead product candidate, is being developed for the potential treatment of myocardial ischemia that gives rise to angina symptoms associated with coronary heart disease. Alferminogene tadenovec represent...

  2. Drug

    Edetate disodium anhydrous

    go.drugbank.com/drugs/DB14600
    ApprovedInvestigationalVet approved

    Edetate disodium anhydrous is a polyvalent chelating agent used to treat hypercalcemia and digitalis toxicity associated ventricular arrhythmias.

  3. Drug

    Dopexamine

    go.drugbank.com/drugs/DB12313
    ApprovedWithdrawn

    Dopexamine has been used in trials studying the diagnostic and treatment of Free Flap, Oral Cancer, Hypotension, Septic Shock, and Head and Neck Cancer.

  4. Drug

    Meticrane

    go.drugbank.com/drugs/DB13284
    Approved

    It has been marketed in Japan under the trade name Arresten and is used to lower blood pressure [L5647].

  5. Drug

    D-3082-L

    go.drugbank.com/drugs/DB17440
    Experimental

    D-3082-L is one of the components of the human papilloma virus (HPV) type 16 E6/E7 synthetic long peptide (SLP) vaccine ISA101b.

    Synonyms: Human Papilloma Virus (HPV) Type 16 E6/e7 Synthetic Long Peptide (SLP) Vaccine Component D-3082-L
  6. Drug

    Palazestrant

    go.drugbank.com/drugs/DB18971
    Investigational

    Palazestrant is under investigation in clinical trial NCT06016738 (OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer).

  7. Drug

    Lexaptepid pegol

    go.drugbank.com/drugs/DB12578
    Investigational

    Lexaptepid pegol has been used in trials studying the treatment of Anemia, Inflammation, Chronic Diseases, End Stage Renal Disease, and Anemia of Chronic Disease.

  8. Drug

    J147

    go.drugbank.com/drugs/DB13957
    Experimental

    J147 is an experimental drug with reported effects against both Alzheimer's disease and ageing in mouse models of accelerated aging. … derivative and a potent neurogenic and neuroprotective drug candidate initially developed for the treatment of neurodegenerative conditions associated with aging that impacts many pathways implicated in

    Synonyms: N-(2,4-Dimethylphenyl)-2,2,2-trifluoro-N'-[(E)-(3-methoxyphenyl)methylene]acetohydrazide
  9. Drug

    Solcitinib

    go.drugbank.com/drugs/DB19856
    Investigational

    Solcitinib is under investigation in clinical trial NCT01777256 (An Adaptive Phase II Study to Evaluate the Efficacy, Pharmacodynamics, Safety and Tolerability of GSK2586184). … The usage of the INN stem '-citinib' in the name indicates that Solcitinib is a Janus kinase inhibitor.

  10. Drug

    Oxidronic acid

    go.drugbank.com/drugs/DB14159
    Approved